ALHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alignment Healthcare Inc (ALHC) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has positive analyst ratings and a bullish technical setup, the lack of recent news catalysts, negative financial performance, and hedge fund selling activity suggest caution. The stock may be better suited for monitoring rather than immediate investment.
The technical indicators for ALHC are mixed but lean slightly bullish. The MACD is positive and contracting, the RSI is neutral at 61.122, and the moving averages show a bullish trend (SMA_5 > SMA_20 > SMA_200). However, the stock is trading close to its pivot level of 20.313, with resistance at 22.288 and support at 18.338.
Analysts have raised price targets significantly, with targets ranging from $25 to $28, indicating confidence in future growth.
Revenue increased by 44.43% YoY in Q4 2025, showing strong top-line growth.
Bullish moving averages suggest potential upward momentum.
Hedge funds are selling heavily, with a 1606.19% increase in selling activity last quarter.
Net income and EPS have dropped significantly YoY, with net income down -64.60% and EPS down -68.75%.
No recent news or event-driven catalysts to support immediate buying.
In Q4 2025, Alignment Healthcare reported a 44.43% YoY revenue increase to $1.012 billion. However, net income dropped to -$11.006 million (-64.60% YoY), and EPS fell to -0.05 (-68.75% YoY). Gross margin improved slightly to 11.4% (+0.44% YoY), but profitability remains a concern.
Analysts are optimistic about ALHC, with multiple firms raising price targets recently. JPMorgan raised the target to $26, Baird to $28, KeyBanc to $28, and TD Cowen to $25. Ratings remain Overweight or Buy, reflecting confidence in the company's long-term potential.
